Related references
Note: Only part of the references are listed.A universal homogeneous assay for high-throughput determination of binding kinetics
Felix Schiele et al.
ANALYTICAL BIOCHEMISTRY (2015)
Rational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA
Cheng-Tsung Lai et al.
BIOCHEMISTRY (2015)
Design strategies to address kinetics of drug binding and residence time
Kevin P. Cusack et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
PHARMACODYNAMICS Which trails are your drugs taking?
Rumin Zhang
NATURE CHEMICAL BIOLOGY (2015)
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Grant K. Walkup et al.
NATURE CHEMICAL BIOLOGY (2015)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Elayne Chan-Penebre et al.
NATURE CHEMICAL BIOLOGY (2015)
Kinetics of protein-ligand unbinding: Predicting pathways, rates, and rate-limiting steps
Pratyush Tiwary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2
Glenn S. Van Aller et al.
ACS CHEMICAL BIOLOGY (2014)
A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA
Huei-Jiun Li et al.
ACS CHEMICAL BIOLOGY (2014)
Pharmacokinetics and the drug-target residence time concept
Goran Dahl et al.
DRUG DISCOVERY TODAY (2013)
Structure-kinetic relationship study of CDK8/CycC specific compounds
Elisabeth V. Schneider et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time
Dong Guo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L
Aravind Basavapathruni et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
Evidence for dynamics in proteins as a mechanism for ligand dissociation
Mary J. Carroll et al.
NATURE CHEMICAL BIOLOGY (2012)
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Georges Vauquelin et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Conformational adaptation in drug-target interactions and residence time
Robert A. Copeland
FUTURE MEDICINAL CHEMISTRY (2011)
Shielded Hydrogen Bonds as Structural Determinants of Binding Kinetics: Application in Drug Design
Peter Schmidtke et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Georges Vauquelin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Drug-target residence time: critical information for lead optimization
Hao Lu et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time
Georges Vauquelin
EXPERT OPINION ON DRUG DISCOVERY (2010)
The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
Robert A. Copeland
EXPERT OPINION ON DRUG DISCOVERY (2010)
Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo
Bonnie Tillotson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis
Sylvia R. Luckner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Slow-Onset Inhibition of the Fabl Enoyl Reductase from Francisella tularensis: Residence Time and in Vivo Activity
Hao Lu et al.
ACS CHEMICAL BIOLOGY (2009)
Potent Inhibitors of HIV-1 Integrase Display a Two-Step, Slow-Binding Inhibition Mechanism Which Is Absent in a Drug-Resistant T66I/M154I Mutant
Edward P. Garvey et al.
BIOCHEMISTRY (2009)
Structural biology contributions to tyrosine kinase drug discovery
Sandra W. Cowan-Jacob et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process
U. Helena Danielson
FUTURE MEDICINAL CHEMISTRY (2009)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Enzymes with lid-gated active sites must operate by an induced fit mechanism instead of conformational selection
Sarah M. Sullivan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues
Lata T. Gooljarsingh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cooperative hydrogen bond interactions in the streptavidin-biotin system
DE Hyre et al.
PROTEIN SCIENCE (2006)
Hepatitis CNS3 protease inhibition by peptidyl-α-ketoamide inhibitors:: kinetic mechanism and structure
YY Liu et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2004)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
Kinetic and structural analysis of the increased affinity of enoyl-ACP (acyl-carrier protein) reductase for triclosan in the presence of NAD+
M Kapoor et al.
BIOCHEMICAL JOURNAL (2004)
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model
AW Norman et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The relationship between side reactions and slow inhibition of ribulose-bisphosphate carboxylase revealed by a loop 6 mutant of the tobacco enzyme
FG Pearce et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia
D Seiffert et al.
BLOOD (2003)
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors
PO Markgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated
JT Billheimer et al.
BLOOD (2002)
The crystal structure of tetrameric methionine adenosyltransferase from rat liver reveals the methionine-binding site
B González et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
